Literature DB >> 23382572

Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Edward E Walsh1, Derick R Peterson, Aja E Kalkanoglu, Frances Eun-Hyung Lee, Ann R Falsey.   

Abstract

BACKGROUND: Comprehensive analyses of host, viral, and immune factors associated with severe respiratory syncytial virus (RSV) infection in adults have not been performed.
METHODS: Adults with RSV infection identified in both outpatient and inpatient settings were evaluated. Upper and lower respiratory tract virus load, duration of virus shedding, select mucosal chemokine and cytokine levels, humoral and mucosal immunoglobulin responses, and systemic T-cell responses were measured.
RESULTS: A total of 111 RSV-infected adults (61 outpatients and 50 hospitalized patients) were evaluated. Hospitalized subjects shed virus in nasal secretions at higher titers and for longer durations than less ill outpatients, had greater mucosal interleukin 6 (IL-6) levels throughout infection, and had higher macrophage inflammatory protein 1α (MIP-1α) levels early in infection. Persons >64 years old and those with more severe disease had a higher frequency of activated T cells in the blood than younger, less ill subjects at infection. Multivariate analysis found that the presence of underlying medical conditions, female sex, increased mucosal IL-6 level, and longer duration of virus shedding were associated with severe disease. Older age and increased nasal MIP-1α levels were of borderline statistical significance.
CONCLUSIONS: Multiple factors, but not older age, are independently associated with severe RSV infection in adults. The presence of underlying medical conditions had the greatest influence on disease severity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23382572      PMCID: PMC3610422          DOI: 10.1093/infdis/jit038

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

Review 1.  Respiratory syncytial virus and parainfluenza virus.

Authors:  C B Hall
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

2.  Serum antibody decay in adults following natural respiratory syncytial virus infection.

Authors:  Ann R Falsey; Harjot K Singh; Edward E Walsh
Journal:  J Med Virol       Date:  2006-11       Impact factor: 2.327

3.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

4.  The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects.

Authors:  F Eun-Hyung Lee; Edward E Walsh; Ann R Falsey; Nathaniel Liu; Dacheng Liu; Anagha Divekar; Jennifer E Snyder-Cappione; Tim R Mosmann
Journal:  Mech Ageing Dev       Date:  2005-11       Impact factor: 5.432

5.  Respiratory syncytial virus infections in previously healthy working adults.

Authors:  C B Hall; C E Long; K C Schnabel
Journal:  Clin Infect Dis       Date:  2001-08-21       Impact factor: 9.079

Review 6.  Immune responses and disease enhancement during respiratory syncytial virus infection.

Authors:  Peter J M Openshaw; John S Tregoning
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

8.  Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults.

Authors:  Coley B Duncan; Edward E Walsh; Derick R Peterson; F Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

9.  Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects.

Authors:  Maria Grazia Cusi; Barbara Martorelli; Giuseppa Di Genova; Chiara Terrosi; Giuseppe Campoccia; Pierpaolo Correale
Journal:  Immun Ageing       Date:  2010-10-20       Impact factor: 6.400

10.  Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.

Authors:  Vivian Luchsinger; Pedro A Piedra; Mauricio Ruiz; Enna Zunino; María Angélica Martínez; Clarisse Machado; Rodrigo Fasce; María Teresa Ulloa; Maria Cristina Fink; Pamela Lara; Luis F Avendaño
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

View more
  50 in total

1.  Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection.

Authors:  Caroline M Percopo; Michelle Ma; Todd A Brenner; Julia O Krumholz; Timothy J Break; Karen Laky; Helene F Rosenberg
Journal:  J Immunol       Date:  2018-12-21       Impact factor: 5.422

Review 2.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

3.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

4.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

5.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

6.  Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Authors:  Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Differential impact of respiratory syncytial virus and parainfluenza virus on the frequency of acute otitis media is explained by lower adaptive and innate immune responses in otitis-prone children.

Authors:  David Verhoeven; Qingfu Xu; Michael E Pichichero
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

8.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

9.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

10.  Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus.

Authors:  Elisa H Fleming; Eliana E Ochoa; Joan E Nichols; M Kerry O'Banion; Alan R Salkind; Norbert J Roberts
Journal:  J Med Virol       Date:  2017-09-26       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.